


PHARMACEUTICAL 2022

Oncotelic Therapeutics Inc. Rank 290 of 475





PHARMACEUTICAL 2022

Oncotelic Therapeutics Inc. Rank 290 of 475

The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 434% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -173%, being 104% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	627
Cost of Goods Sold	0
Intangible Assets	21,884
Liabilities, Current	15,455
Liabilities, Non-Current	0
Other Assets	1,102
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,391
Property and Equipment	0
Research and Development	3,659
Revenues	0
Selling, General and Administrative Expense	5,467

Output Variable	Value in 1000 USD
Assets	23,613
Liabilities	15,455
Expenses	9,126
Stockholders Equity	8,158
Net Income	-10,517
Comprehensive Net Income	-10,517
Economic Capital Ratio	-173%